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Background: WIN-34B is a novel Oriental medicine, which represents the n-butanol fraction prepared from dried
flowers of Lonicera japonica Thunb and dried roots of Anemarrhena asphodeloides BUNGE. The component herb of
WIN-34B is used for arthritis treatment in East Asian countries. The aim of this study was to determine the
cartilage-protective effects and mechanisms of WIN-34B and its major phenolic compounds, chlorogenic acid and
mangiferin, in osteoarthritis (OA) human cartilage explants culture and chondrocytes.
Methods: The investigation focused on whether WIN-34B and its standard compounds protected cartilage in
interleukin (IL)-1β-stimulated cartilage explants culture and chondrocytes derived from OA patients. Also, the
mechanisms of WIN-34B on matrix metalloproteinases (MMPs), tissue inhibitor of matrix metalloproteinases (TIMPs),
inflammatory mediators, and mitogen-activated protein kinases (MAPKs) pathways were assessed.
Results: WIN-34B was not cytotoxic to cultured cartilage explants or chondrocytes. WIN-34B dose-dependently
inhibited the release of glycosaminoglycan and type II collagen, increased the mRNA expression of aggrecan and
type II collagen, and recovered the intensity of proteoglycan and collagen by histological analysis in
IL-1β-stimulated human cartilage explants culture. The cartilage protective effect of WIN-34B was similar to or better
than that of chlorogenic acid and mangiferin. Compared to chlorogenic acid and mangiferin, WIN-34B displayed
equal or greater decreases in the levels of MMP-1, MMP-3, MMP-13, ADAMTS-4, and ADAMTS-5, and markedly
up-regulated TIMP-1 and TIMP-3. WIN-34B inhibited inflammatory mediators involved in cartilage destruction, such
as prostaglandin E2, nitric oxide, tumor necrosis factor-alpha, and IL-1β. The phosphorylation of extracellular
signal-regulated kinase, c-Jun N-terminal kinase (JNK), and p38 was significantly reduced by WIN-34B treatment,
while phosphorylation of JNK was only inhibited by chlorogenic acid or mangiferin in IL-1β-stimulated
chondrocytes.
Conclusions: WIN-34B is potentially valuable as a treatment for OA by virtue of its suppression of MMPs, ADAMTSs,
and inflammatory mediators, and it’s up-regulation of TIMP-1 and TIMP-3 involved in the MAPK pathway.
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Osteoarthritis (OA) is a multifactorial degenerative joint
disease in which the cartilaginous matrix of the articular
joint is destroyed. The anabolic and catabolic imbalance
in articular cartilage plays a crucial role in OA pathogen-
esis. As a result, enhanced degradation occurs in the
macromolecular components including aggrecan and
collagen [1]. The superficial zone of OA cartilage, which
is characterized by degenerative changes (fibrillations,
chondrocyte clusters, and degenerative matrix changes)
contains interleukin (IL)-1β, tumor necrosis factor-alpha
(TNF-α), and matrix metalloproteinases (MMPs) includ-
ing MMP-1, 2, 3, 8, 9, and 13 [2]. IL-1β and TNF-α can
induce chondrocytes to produce other cytokines as well
as stimulate catabolic proteinases (MMPs or aggreca-
nases) and proinflammatory mediators such as nitric
oxide (NO) and prostaglandin E2 (PGE2) [3]. In this way,
they can alter compensatory biosynthetic homeostasis
and, in turn, break down the integrity of the extracellular
matrix (ECM) [4-6].
The disease progression and structural changes show
that the release of sulfated glycosaminoglycan (GAG),
the degradation of type II collagen, and the over-
production of cytokines are central pathophysiological
events in OA. The course of the disease is related to a
number of complex pathways and mechanisms, among
which are the excessive production of proteolytic enzymes
such as the aggrecanases and MMPs [4-6]. Aggrecan is
degraded by both aggrecanases and MMPs, whereas type
II collagen is degraded by MMPs [6]. With these protease
activities in mind, it is logical to target these actions to
stop the progression of cartilage degradation in OA.
IL-1β can induce chondrocytes to produce proinflam-
matory mediators such as PGE2 and NO, as well as stimu-
lating catabolic proteinases (MMPs or aggrecanases) [1-3].
NO is a crucial mediator of the inflammatory response by
virtue of its physiological effects and its ability to regulate
the expression of inflammatory proteins [3]. In this way,
they can alter compensatory biosynthetic homeostasis and
break down the integrity of the ECM [4-7].
Recent studies have demonstrated that mitogen-
activated protein kinases (MAPKs) play a key role in the
cytokine regulation of MMP expression and consequent
cartilage destruction [8]. In OA cartilage, the level of
phosphorylated MAPKs, including extracellular signal-
regulated kinase (ERK), c-Jun amino-terminal kinase
(JNK), and p38 appears to be higher than that in normal
cartilage [9]. MAPK pathways can be specifically activates
downstream to over-production of MMP-1, -3, and −13,
TNF-α, and NO [10-12]. However, the precise down-
stream mechanism is unknown, which limits effective
therapeutic interventions in OA.
While various attempts have been made to develop
disease-modifying OA drugs (DMOADs) that neutralizeinflammatory cytokines and proteinases, enhance factors
related to cartilage and bone homeostasis, and intervene
in intracellular signaling pathways, the results to date
have been unsatisfactory regarding the effects and safety
of these drugs [13,14]. The combination of systemic and
topical administration of non-steroidal anti-inflammatory
drugs (NSAIDs), steroids, glucosamine, and opioids is
generally prescribed for OA patients, but current treatment
options for more effective and safer management of
chronic OA are insufficient [15-17]. Along with the alle-
viation of clinical symptoms, more effective therapeutic
strategies to prevent the progression of disease and aid in
the recovery of tissue damage are needed [18]. As an alter-
native to the existing treatment, research into natural
materials derived from herbs utilized for the safe cure for
OA has been done.
To develop a novel OA treatment, we investigated the
cartilage protection, analgesia, and anti-inflammation
properties of 200 medicinal herbs used clinically for
their anti-inflammatory and analgesic properties in trad-
itional medicine. WIN-34B, a compound extracted from
two herbs, the flowers of Lonicera japonica Thunb and
roots of Anemarrhena asphodeloides BUNGE, was
selected from the screen. WIN-34B demonstrated excel-
lent anti-inflammatory, analgesic, and anti-osteoarthritic
properties in the experimental animal models [19], and
did not cause any acute or chronic toxicity or gastric
mucosal damage in the animal models [20].
In this study, we investigated whether WIN-34B and its
standard compounds have cartilage protective effects in
IL-1β induced human cartilage explants culture. We
assessed the viability of WIN-34B in the presence or
absence of IL-1β-induced cartilage explants culture and
chondrocytes, levels of GAG and type II collagen, histo-
chemical features, levels of matrix proteinases [ADAMTSs,
MMPs, and tissue inhibitors of matrix metalloproteinase
(TIMPs)] and inflammatory mediators (PGE2, NO, IL-1β,
and TNF-α) and the phosphorylation of MAPK signaling.Methods
Preparation of WIN-34B
WIN-34B was prepared by extracting a mixture of two
medicinal herbs (dried flowers of Lonicera japonica
and dried roots of Anemarrhena asphodeloides) at a
respective ratio of 2:1 (w/w) with 50% (v/v) ethanol for
4 h at 85°C. After the extracted solution was filtered
and evaporated in vacuo, the resulting concentrate was
dissolved in 225 ml of distilled water and partitioned
with 195 ml of n-butanol. The n-butanol layer was eva-
porated in vacuo and lyophilized for complete removal
of the residual solvent to give 11 g of brown powder,
for a yield of 7%. WIN-34B was standardized for qual-
ity control according to a previous report [19].
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of WIN-34B
WIN-34B was standardized for quality control according
to a previous report [19], and used high pressure liquid
chromatography (HPLC) analysis to identify the standard
compounds, mangiferin and chlorogenic acid. Chromato-
graphic analysis of WIN-34B was performed with a
reverse-phase HPLC system (Waters, Milford, MA)
equipped with the Waters Breeze System (2695 Separa-
tions Module, 996 Photodiode Array Detector, Empower 2
Software Build 2154). Separation was carried out using a
YMC Hydrosphere C18 column (4.6 × 250 mm, particle
diameter of 5 μm, YMC, Kyoto, Japan) at 30°C. The mo-
bile phase consisted of 0.1% phosphoric acid solution
in pump A (88.8%) and acetonitrile in pump B. Elution
was undertaken using step gradients [B; 11.2-11.2%
(0–16 min), 11.2-13.2% (16–17 min), 13.2-13.2%
(17–28 min), and 13.2–100% (28–33 min)] at a flow rate
of 1.0 ml/min. Detection of chlorogenic acid and mangi-
ferin were performed at 327 nm and 254 nm, respectively
(Figure 1).
Cartilage explants culture
The collection of human OA cartilage was approved by
medical ethical regulations of the Kyung Hee University
Medical Center (KHMC-IACUC-2010011) and was
obtained from the femoral chondyle and tibia plateau
after nine patients undergoing total knee arthroplasty at
the Kyung Hee University Medical Center provided con-
sent. The average patient age was 62 years and patients
included two males and seven females. NSAID medica-
tion was stopped 7 days before surgery and previous
medication use was not expected to interfere with the
studies. Two orthopedists read sites from all regions of
the knee joint under a microscope. Only cartilage that
appeared to be of full thickness with significant fibrilla-
tion was selected, so most joints appeared worse than
the cartilage used here. Cartilage slices were aseptically
cut as thick as possible from the articular bone surface,
cut into square pieces, aseptically weighed (range 25 ±
0.1 mg), and cultured individually in 48-well plates with
400 μl of complete culture medium. The complete cul-
ture medium consisted of Dulbecco’s modified Eagle’s
medium (DMEM) supplemented with 10 mM HEPES,
penicillin (100 IU/ml), streptomycin (100 μg/ml), and
5% fetal bovine serum (FBS). After 24 h, the cartilage
medium was changed to basal culture medium (DMEM
supplemented with 10 mM HEPES, 100 IU/ml penicillin,
100 μg/ml streptomycin, and 2% FBS).
WIN-34B treatment of human cartilage explants culture
Experimental groups consisted of IL-1β-unstimulated
control group, IL-1β-treated group (10 ng/ml), IL-1β-
treated group with WIN-34B (40, 100, 200 μg/ml), IL-1β-treated group with chlorogenic acid (CA; 40, 100,
200 μg/ml; Sigma-Aldrich, St. Louis, MO, USA), and IL-
1β-treated group with mangiferin (MF; 40, 100, 200 μg/ml;
Sigma-Aldrich). Cartilage pieces were placed in 48-well
plates and treated with 10 ng/ml human recombinant IL-
1β (R&D Systems, Minneapolis, MN, USA) in basal cul-
ture medium. After 1 h of pretreatment, WIN-34B, CA, or
MF was added to the basal culture media and then cul-
tures were incubated in a humidified 5% CO2 incubator at
37°C. Reagents were replaced every 3 days, and superna-
tants were harvested at 7, 14, and 21 days. Supernatants
were stored at −20°C until assayed.
Cytotoxicity assay
As an indicator of cytotoxicity, the cytoplasmic enzyme
lactate dehydrogenase (LDH) was measured in the cul-
ture medium. An optimized LDH test (Promega, Madi-
son, WI, USA) was used to quantify LDH activity in the
medium of the cartilage explants culture.
GAG degradation assay
The level of GAG in the cartilage explants culture
medium at 7, 14, and 21 days was determined by meas-
uring the amount of polyanionic material reacting with
1, 9-dimethylmethylene blue. Twenty microliter samples
were mixed with 100 μl of DMB reagent (48 mg/ml
DMB, 40 mM glycine, 40 mM NaCl, 10 mM HCl, pH 3.0)
for 30 min at room temperature and quantified spectro-
photometrically at 590 nm in a Spectramax apparatus
(Molecular Devices, Sunnyvale, CA, USA). All measure-
ments were performed in quadruplicate. Quantification
was performed using a standard curve of chondroitin
6-sulfate from shark cartilage (Sigma-Aldrich) in the
range of 0–35 μg/ml. Protein concentrations of the culture
supernatants were also measured using the Bradford
method (Pierce, Rockford, IL, USA) and then converted
into μg/mg.
Type II collagen degradation assay
Type II collagen levels in the medium of the cartilage
explants culture at 7, 14, and 21 days was determined
using the Sircol Type II Collagen Assay Kit (Biocolor,
Carrickfergus, Northern Ireland). Samples (100 μl) were
mixed with Sirius red dye containing sulfonic acid,
which reacts specifically with the basic side chain groups
of type II collagens, for 30 min at room temperature
using a mechanical mixer. After centrifuging for 10 min
at 12,000 rpm, the unbound dye was removed, and the
dye bound to type II collagen was dissolved in 0.5 N
NaOH. Absorbance was measured at 540 nm using a
Spectramax ELISA reader (Molecular Devices). All mea-
surements were performed in quadruplicate. Concentra-





















Figure 1 Representative HPLC chromatogram of the extracts of WIN-34B and its standard compounds. HPLC chromatogram of WIN-34B
(A), major compound of chlorogenic acid (B) and mangiferin (C). Chlorogenic acid was detected at approximately 14 min and mangiferin was
detected at approximately 18 min at 254 nm in this system.
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Reverse transcriptase-polymerase chain reaction (RT-PCR)
Total RNA was extracted from OA cartilage explants by
homogenizing with TRIzol reagent (Gibco Life Tech-
nologies, Grand Island, NY, USA) according to the man-
ufacturer's instructions. Reverse transcription of thetotal RNA was carried out for 60 min at 42°C followed
by 15 min at 72°C using an RT-PCR system (TaKaRa
Bio, Seoul, Korea), which contained RT buffer, oligo
(dT) 12-mer, 10 mM dNTP mix, 0.1 M dithiothreitol, re-
verse transcriptase, and RNase inhibitor. PCR using spe-
cific primers for each cDNA was carried out in a PCR
reaction volume of 10 μl supplemented with 2.5 units of
TaKaRa Taq™, 1.5 mM each dNTP, 1× PCR buffer, and
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ation for 5 min at 95°C, 35 amplification cycles were
performed for aggrecan, type II collagen, ADAMTS-4,
ADAMTS-5, MMP-1, MMP-3, MMP-13, TIMP-1, and
TIMP-3 (one cycle = 1 min at 95°C for denaturation,
1 min at 55°C for annealing, and 1.5 min at 72°C for ex-
tension), as well as for β-actin (one cycle = 1 min at 95°C
for denaturation, 1 min at 58°C for annealing, and
1.5 min at 72°C for extension). After amplification, PCR
products were separated by electrophoresis on 1.8%
agarose gels and visualized using ethidium bromide
staining and ultraviolet irradiation.Histological analysis
Cartilage explants pieces were fixed in 10% neutral for-
malin, dehydrated with graded ethanol, embedded in
paraffin, and sectioned into 4 μm-thick slices. Sectioned
tissues were deparaffinized and stained with Safranin O
and Masson's Trichrome to detect proteoglycan and col-
lagen in the cartilage. The staining intensities of Safranin
O and Masson's Trichrome were quantified by i-solution
program (IMT i-solution, Seoul Korea) after capture
using an Axiocam MRc5 CCD camera (Carl Zeiss, Jena,
Germany) at x40 magnification on histologic sections. A
pathologist with no prior knowledge of the test reagents
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aFw, forward; Rv, reverse; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; Tm,Enzyme-linked immunosorbant assay (ELISA)
The levels of MMP-1, MMP-3, MMP-13, TIMP-1,
TIMP-3, IL-1β, and TNF-α in conditioned media from
OA cartilage explants at 7 days were measured using
human ELISA kits (R&D Systems), according to the
manufacturer's instructions.
Aggrecanase activity assay
Conditioned medium in cartilage explants at 7 days from
the onset of culture was incubated in the presence of
1% w/v bovine serum albumin (BSA) in phosphate buf-
fered saline (PBS)/Tween 20 (0.05% v/v) for 2 h at 25°C
on a 96-well plate (Biosource) containing a monoclonal
antibody that recognizes KS chains and, according to the
manufacturer, is not impacted by other non-KS glycosa-
minoglycans, including hyaluronic acid, chondroitin
sulfate, and heparin sulfate. Fragments containing
ARGSVIL neoepitope were detected using biotinylated
monoclonal antibody (mAb) OA-1 (PIERCE, Rockford,
IL, USA). Levels of bound biotinylated mAb OA-1 were
detected using 1 μg/ml streptavidin-horseradish peroxid-
ase (HRP) and TMB as a substrate. Absorbance was
determined following acidification using a microplate
reader at a wavelength of 450 nm. Calibration curves for
standard ARGSVIL peptide were run in parallel, and the
amounts of ARGSVIL peptide produced in hydrolytic






















Huh et al. BMC Complementary and Alternative Medicine 2012, 12:256 Page 6 of 14
http://www.biomedcentral.com/1472-6882/12/256Measurement of PGE2
PGE2 production was determined from the supernatant
of cultured OA cartilage explants at 7 days using assay
kits (R&D Systems) performed per the manufacturer’s
instructions.
Measurement of NO
NO synthesis was determined from the supernatant of
cultured OA cartilage explants at 7 days by colorimetric
assay as an indicator of NO production. Briefly, a 100 μl
aliquot of medium was mixed with 100 μl of Greiss
reagent (1% sulfanilamide in 5% phosphoric acid and
0.1% naphthylethylenediamine dihydrochloride in water)
(Sigma-Aldrich) in flat-bottom, 96-well immunoassay
plates (SPL Life Sciences, Seoul, Korea). After incubating
for 10 min at room temperature, absorption was mea-
sured at 550 nm with a Spectra Max 340 multichannel
spectrophotometer (Molecular Devices). The nitrite con-
centration was determined from a standard curve gener-
ated using sodium nitrite (NaNO2).
Culture of chondrocytes and treatment
Chondrocytes were isolated from pooled femoral and
tibial cartilage from individual OA patients by incubat-
ing with 1 mg/ml trypsin (Sigma-Aldrich) for 1 h fol-
lowed by an overnight digestion in 0.5 mg/ml type II
collagenase. The following morning, the isolated chon-
drocytes were washed with complete medium and
counted at 1x106 cells/ml.
Chondrocytes viability
Cells were pipetted (100 μl, 1 × 105 cells/well) into a flat
bottom 96-well culture plate and different concentra-
tions of WIN-34B, chlorogenic acid, and mangiferin (10,
40, 100, 200, and 1000 μg/ml) were added in the pres-
ence or absence of 10 ng/ml IL-1β. After 48 h incuba-
tion at 37°C, 10 μl bromodeoxyuridine (BrdU) was
added to each well, and the samples were incubated for
6 h at 37°C. Cells were fixed, anti-BrdU-peroxidase
(POD) was added, and then detection was performed
using the 3,30,5,50-tetramethylbenzidine (TMB) substrate
reaction. The reaction product was quantified using an
ELISA reader (480–650 nm).
Western blot analysis
For Western blot analysis of ADAMTS-4 and MAPK
signaling pathways, pieces of cartilage explants culture
were immediately frozen in liquid nitrogen and proteins
in the resulting powder were extracted with Tris buffer
(50 mM Tris, pH 7.0, 100 mM NaCl and 1 μg/ml aproti-
nin, 0.7 mg/ml pepstatin, 1 mg/ml leupeptin, and 1 mM
phenylmethylsulfonyl fluoride) for 12 h. Extract were
lyophilized for 2 h to concentrate the proteins, and
quantified by the Bio-Rad protein assay. Total protein(20 μg) was separated by electrophoresis by 10% sodium
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE) and transferred onto a Hybond-C nitrocellulose
membrane (Amersham Biosciences, Piscataway, NJ,
USA). Blots were blocked in TBS-T containing 5% dry
milk for 1 h. Thereafter, blots were probed with a poly-
clonal antibody against ADAMTS-4 (abcam-ab; Dawinbio,
Seoul, Korea; 1:500 dilution), anti-phospho-ERK-1/2,
phospho-p38, phospho-JNK, ERK, p38, and JNK (Cell Sig-
naling Technology, Danvers, MA, USA), β-actin or non-
immune mouse IgG (Sigma-Aldrich) in blocking buffer at
4°C overnight. Subsequently, each membrane was washed
in TBS-T buffer five times for 5 min. Detection was
carried out using anti-rabbit hoseradish peroxidase-
conjugated IgG (Sigma-Aldrich, 1:5000 dilution) in
blocking buffer. Blots were developed by enhanced
chemiluminescence (ECL).
For measuring MMP-1, and MMP-13 expression level
in IL-1β-stimulated cartilage explants culture, total
secreted proteins from 2 ml of conditioned medium
were harvested and concentrated by precipitation with
trichloroacetic acid (TCA). Proteins (10 μg) were sepa-
rated by 10% SDS-PAGE. Blots were treated as described
above. Membrane were incubated with specific anti-
bodies to MMP-1 and MMP-13 (Calbiochem, San Diego,
CA, USA; 1:1000 dilution) in blocking buffer at 4°C
overnight, and secondary antibody (Sigma, 1:5000) for
2 h at room temperature. Band intensities were quanti-
fied by NIH ImageJ 1.32j (National Institute of Health,
USA) software.
Statistical analyses
Results are expressed as the mean ± SEM. Differences
among groups were analyzed by one-way ANOVA fol-
lowed by Dunnett’s post-hoc test. In the case of two
groups, a Student's t-test was used. Statistical signifi-
cance was assessed at p < 0.05. Experiments were inde-
pendently triplicated and results were qualitatively
identical. Representative experiments are shown.
Results
Effect of WIN-34B on the cytotoxicity of cartilage explants
culture and chondrocytes
WIN-34B was not cytotoxic, as judged by the absence of
significant change in LDH activity in the culture
medium in the presence or absence of IL-1β. MF did
not affect the cytotoxicity of cartilage explants culture in
the absence of IL-1β, but a high concentration of MF
(1000 μg/ml) was cytotoxic in the presence of IL-1β. CA
increased LDH leakage in the culture medium of human
OA cartilage explants in the presence or absence of IL-
1β (Figure 2A). In chondrocytes, WIN-34B in doses ran-
ging from 0.1–1000 μg/ml did not show the significant
effect on the viability of chondrocytes, while viability of
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Figure 2 Effect of WIN-34B and its major compounds on the cytotoxicity of IL-1β-stimulated human cartilage explants culture and
chondrocytes.
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(Figure 2B). MF or CA at 1000 μg/ml inhibited the via-
bility by about 30% and 40%, respectively, in the absence
of IL-1β, suggesting a possible cytotoxic effect at this
concentration (Figure 2B). However, the effect of MF or
CA on the viability of chondrocytes did not exceed IC50
at concentration up to 200 μg/ml (Figure 2B).
Effect of WIN-34B on the level of proteoglycan and type II
collagen in IL-1β-stimulated cartilage explants culture
In preliminary experiments, to optimize the conditions
with which to induce proteoglycan and collagen degrad-
ation, articular cartilage was cultured with 1, 2.5, 5, 10,
or 20 ng/ml IL-1β for 21 days. These effects were dose-
dependent, and 5 ng/ml IL-1β was required to consis-
tently achieve the maximal response. In experimentalcultures of cartilage treated with 10 ng/ml IL-1β, more
than 7.8 mg/mg of GAG had been released from the
tissue after 7 days of culture, and about 7.5 mg/mg after
21 days (Figure 3A), while the release of type II collagen
was marginal at any concentration of IL-1β for 7 days,
after which there was a marked increase in collagen
release to about 75% by 21 days of culture (Figure 3A).
WIN-34B, CA, or MF at 100 μg/ml reduced the GAG
release until 21 days, but the effect of WIN-34B was
superior to CA or MF (Figure 3B). WIN-34B in doses
ranging from 40–200 μg/ml significantly inhibited about
28%–49% of the release of GAG at 7 days, while CA and
MF displayed no significant differences compared with
IL-1β-stimulated cartilage explants culture (Figure 3C).
After 21 days, WIN-34B, CA or MF reduced the release
of type II collagen in the explants relative to that in
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Figure 3 Effect of WIN-34B and its major compounds on cartilage protection of IL-1β-stimulated human cartilage explants culture.
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http://www.biomedcentral.com/1472-6882/12/256IL-1β-treated cultures (Figure 3D), and the degradation of
type II collagen was significantly reduced by about 13%–
74% by WIN-34B, 11%–62% by CA, and 5%–49% by MF
compared with IL-1β treatment in cartilage explants
culture (Figure 3E). Also, the mRNA expression of aggrecan
and type II collagen was significantly decreased by IL-1β
treatment and was almost normalized by WIN-34B at
100 μg/ml IL-1β-stimulated cartilage explants culture
(Figures 3F and 3 G). On the contrary, CA and MF
were unable to affect the level of aggrecan compared with
IL-1β-stimulated cartilage explants culture (Figures 3F and
3G). The intensity of Safranin O staining was significantly





























































Figure 4 Histochemical analysis of proteoglycan and collagen in IL-1βcompared with IL-1β in cartilage explants culture
(Figures 4A and 4B). WIN-34B at 100 μg/ml also signifi-
cantly enhanced the intensity of Masson’s Trichrome stai-
ning by about 5.2-fold compared with IL-1β (Figures 4A
and 4C). The difference between WIN-34B and CA or MF
was especially pronounced on the contents of proteoglycan
and collagen (Figures 4A–4C).
Effect of WIN-34B on the levels of aggrecanases, MMPs,
and TIMPs in IL-1β-stimulated cartilage explants culture
WIN-34B significantly inhibited the mRNA expression
of ADAMTS-4, ADAMTS-5, MMP-1, MMP-3, and
MMP-13, and enhanced the mRNA level of TIMP-1 and100 100
    CA         MF
( g/ml)
100 100
       CA           MF
( g/ml)
*
-stimulated human cartilage explants culture.
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34B in doses from 40–200 μg/ml produced a significant re-
duction of aggrecanases activity ranging from 32%–80%,
but there were no significant changes by CA and MF
(Figure 5B). WIN-34B produced a dose-dependent reduc-
tion ranging from 15%–66% of MMP-1, 42%–80% of
MMP-3, and 32%–86% of MMP-13, while WIN-34B sig-
nificantly induced production of TIMP-1 (8%–74%) and
TIMP-3 (32%–89%) in IL-1β-stimulated cartilage explants
culture (Figure 5B). Notably, the reduction of aggrecanases,
MMP-1, MMP-3, and MMP-13 by WIN-34B and the
enhancement of TIMP-1 and TIMP-3 were superior to the
effect seen with CA or MF (Figure 5B). In addition, WIN-
34B dose-dependently inhibited the protein expression
of ADAMTS-4, MMP-1, and MMP-13 in conditioned
medium from IL-1β-stimulated cartilage explants culture.
However, CA and MF only slightly inhibited the protein
expression of MMP-1 and MMP-13 (Figure 5C).
Effects of WIN-34B on inflammatory mediators in
IL-1β-stimulated cartilage explants culture
WIN-34B in doses ranging from 40–200 μg/ml significantly
inhibited 16%–83% of PGE2 release, 17%–59% of NO pro-
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Figure 5 Effect of WIN-34B and its major compounds on the level of
human cartilage explants.compared with IL-1β − stimulated cartilage explants culture
(Figures 6A–6D). CA significantly inhibited the release of
PGE2 production of IL-1β and TNF-α, while CA was
unable to affect the level of NO in IL-1β-stimulated human
cartilage explants culture (Figures 6A–6D). MF markedly
decreased the production of IL-1β and TNF-α, but did not
affect PGE2 and NO secretion in IL-1β-stimulated cartilage
explants culture (Figures 6A–6D).
Effect of WIN-34B on phosphorylation of MAPKs in
IL-1β-stimulated cartilage explants culture
The phosphorylation of ERK, JNK, and p38 MAPKs was
reduced by 25%, 59%, and 63%, respectively, upon treat-
ment with WIN-34B at 100 μg/ml compared with IL-
1β − stimulated stimulated cartilage explants culture
(Figure 7A). CA and MF dose-dependently inhibited JNK
phosphorylation and increased the phosphorylation of p38,
while not affecting the phosphorylation of ERK in IL-1β-
stimulated cartilage explants culture (Figures 7B and 7C).
Discussion
A problem in using natural herbal material is the diffi-
culty in standardization of efficacy, which is partially due
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Figure 6 Effect of WIN-34B and its major compounds on the productions of inflammatory mediators in IL-1β-stimulated cartilage
explants culture.
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http://www.biomedcentral.com/1472-6882/12/256period, and cultivation time. Also, for the discovery and
development of new treatments, further understanding
of the processes leading to disease progression and in
particular, the pathways leading to the expression of the
MMPs, aggrecanases, and cartilage destruction are of
pivotal importance. Therefore, we measured the major
components and examined their efficacy to set a stan-
dard for use of WIN-34B in practice and in medicine
development. In this study, we demonstrated the cartilage-
protective effects of WIN-34B compared to standard com-
pounds, CA and MF, in IL-1β-stimulated cartilage explants
culture. WIN-34B more effectively improved the cartilage
protection without cytotoxicity by modulating MMPs,
ADADMTs, TIMPs, and inflammatory mediators, and
possibly by inhibiting MAPK pathways.
WIN-34B did not exert cytotoxic effects in the absence
of IL-1β in human OA cartilage explants culture and did
not affect cell viability in chondrocytes. However, CA
was cytotoxic in human cartilage explants culture and
chondrocytes.
Previously, we found that even high doses of WIN-34B
did not cause toxicity or gastric injury when orally admi-
nistered to rats [20]. Both single and multiple doses of
WIN-34B had no effect on mortality, body weightchanges, gross findings, or clinical signs in patients of
either sex [19]. This finding was in contrast to those for
diclofenac and celecoxib, which cause inflammation and
hemorrhage [19,20]. Furthermore, clinical study on
patients with OA revealed that WIN-34B not only had a
good analgesic efficacy and safety profile, but also showed
functional improvements on the time taken to go up and
down a standard flight of stairs, duration of morning stiff-
ness, and softening of the affected knee joint. These
results support the safety and therapeutic usefulness of
WIN-34B for development as an OA treatment.
WIN-34B markedly prevented the release of GAG and
type II collagen, which are associated with the down-
regulation of matrix proteinases (MMP-1, MMP-3,
MMP-13, ADAMTS-4, and ADAMTS-5), inflammatory
cytokines (PGE2, NO, IL-1β, and TNF-α), and up-
regulation of TIMP-1 and TIMP-3 levels in IL-1β-
stimulated human OA cartilage culture. However, CA
and MF significantly inhibited only collagen release,
which is associated with the inhibition of MMP-1, MMP-
13, and inflammatory cytokines in IL-1β-stimulated
human OA cartilage culture. The inhibition of GAG re-
lease and recovery of aggrecan expression by CA and MF
was not evident in IL-1β-stimulated human OA cartilage










































































Figure 7 Effect of WIN-34B and its major compounds on pERK, pJNK, and pp38 MAPK proteins in IL-1β-stimulated human cartilage
explants.
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potential candidate for effective anti-osteoarthritic therapy
with cartilage protective properties better than CA or MF.
Protecting ECM components is critical to modifying
OA progression and protecting joint functions [21,22]. A
number of studies have documented the fact that aggre-
can not only resists mechanical loading by enabling the
cartilage matrix to attract and imbibe water molecules,
but also plays a partial role in preventing collagen deg-
radation in OA pathogenesis [21,23,24]. For this reason,
many researchers have investigated the OA-modifying
effects of drugs designed to inhibit ADAMTS-4 and
ADAMTS-5 [25]. Several studies have reported that glu-
cosamine down-regulates ADAMTS and MMPs inclu-
ding MMP-3, MMP-9, MMP-10, and MMP-12 [25,26].
SKI306X, a commercially-available herbal mixture for
OA treatment, inhibits cartilage degradation through the
production of MMPs and inflammatory mediators [27].
Inflammatory mediators, such as PGE2, NO, IL-1, and
TNF-α, play key roles in the progression of cartilage de-
struction in OA [28,29]. Particularly, IL-1β produces
PGE2 and NO, and stimulates the expression of other
inflammatory cytokines and MMPs [27]. PGE2 is a
pathologic mediator responsible for the remodeling of
cartilage and bone [28]. NO is a pleiotropic mediator
involved in the catabolic process of OA, which inhibits
the synthesis of proteoglycan and collagen, resulting in
the promotion of cartilage destruction [29]. Presently,WIN-34B decreased the level of inflammatory mediators
including PGE2 and NO, as well as the proinflammatory
cytokines, IL-1β, and TNF-α, which are all recognized as
inducers of MMPs and aggrecanases. The inhibition of
PGE2 release, NO production, and TNF-α secretion by
WIN-34B was superior to CA or MF. These results sug-
gest that WIN-34B inhibits the pathologic inflammatory
molecules in the cartilage destruction of OA.
MAPKs regulate pro-inflammatory cytokine produc-
tion and downstream signaling cascades leading to cata-
bolic joint destruction [8,30]. Studies in human cells
have suggested that MAPK signaling is important for
the MMP-derived catabolic response of chondrocytes.
Liacini et al. showed that TNF-stimulated human OA
chondrocytes up-regulated expression of MMP-13,
through MAPK 44/42 and Janus-NH2-terminal kinase
JNK [11]. Similar results in human chondrosarcoma
cells supported these findings [31]. Taken together, these
findings suggest that MAPK signaling is important for the
MMP-derived catabolic response of chondrocytes. Re-
cently reported that intra-articular injections of the p38
MAPK inhibitor SB203580 in the anterior cruciate liga-
ment transection (ACLT) rat model of OA inhibited the
expression of MMP-3 and MMP-13 and protected against
cartilage damage [32]. Other research showed WIN-34B
dose-dependently diminished phosphorylation of ERK,
JNK, and p38 MAPK, as well as MMPs and aggrecanases
in IL-1β-stimulated cartilage explants culture. However,
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pressed phosphorylation of JNK, but did not affect the
phosphorylation of ERK. Inhibition of the MAPK P44/42
pathway by either U0126 or PD98059 leads to abrogation
of the expression and activity of MMPs and aggreca-
nases and ADAMTS. Inhibitors of the p38 MAPK and
JNK pathways were also investigated by SB203580 or
SB202190 and PP1, respectively. However, inhibition of
these pathways resulted in inhibition of MMP expres-
sion and activity, but did not influence aggrecanases
activity [33]. The current line of investigations suggests
that p38 MAPK and JNK activity could be associated
with MMP-mediated irreversible cartilage damage,
whereas the processes needed for normal repair mecha-
nism and aggrecanase activity may in part be controlled
by MAPK p44/42-activities [33,34]. From these results
we can suggest that WIN-34B may be critical role on
cartilage protection and anti-inflammatory effect by
the downregulation of pERK, p38 MAPK and pJNK
signaling pathways.Conclusions
WIN-34B has cartilage protective effects similar to or
better than its standard compound CA or MF through
the regulation of matrix proteinases (aggrecanases and
MMPs/TIMPs), inflammatory mediators (PGE2, NO, IL-
1β, and TNF-α) and the MAPK pathways. These results
suggest that WIN-34B could be a potential candidate for
effective anti-osteoarthritic therapy with cartilage pro-
tective properties and without toxicity instead of existing
OA treatment.
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